Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR

https://doi.org/10.1016/j.bmcl.2010.09.033Get rights and content

Abstract

The Bcl-2 family of proteins plays a major role in the regulation of apoptosis, or programmed cell death. Overexpression of the anti-apoptotic members of this family (Bcl-2, Bcl-xL, and Mcl-1) can render cancer cells resistant to chemotherapeutic agents and therefore these proteins are important targets for the development of new anti-cancer agents. Here we describe the discovery of a potent, highly selective, Bcl-2 inhibitor using SAR by NMR and structure-based drug design which could serve as a starting point for the development of a Bcl-2 selective anti-cancer agent. Such an agent would potentially overcome the Bcl-xL mediated thrombocytopenia observed with ABT-263.

Section snippets

Acknowledgment

Thanks to Steve Swann for assistance in preparing this manuscript.

References and notes (9)

  • D. Hanahan et al.

    Cell

    (2000)
  • H. Zhang et al.

    Anal. Biochem.

    (2002)
  • J. Porter et al.

    Bioorg. Med. Chem. Lett.

    (2009)
  • C. Tse et al.

    Cancer Res.

    (2008)
There are more references available in the full text version of this article.

Cited by (62)

  • Applications of “linkers” in fragment-based drug design

    2022, Bioorganic Chemistry
    Citation Excerpt :

    And when the hydrophobic substituent was added back to the core of the diphenylmethane in the linker compound, the most potent compound 21 was obtained by modification, and the Kd value could reach 40 nM. Thus this linker moiety could provide a useful starting point for the development of effective Bcl-2 selective antitumor drugs [38]. To find new LDH-A inhibitors, Kohlmann et al. used a fragment-based approach to identify low-molecular-weight compounds-oxaline, which binds to LDH-A, and introduced flexible linkers of seven to nine atoms to connect the space between the two oxaline variant molecules.

  • Discovery of novel biaryl sulfonamide based Mcl-1 inhibitors

    2019, Bioorganic and Medicinal Chemistry Letters
  • Potent and Selective EphA4 Agonists for the Treatment of ALS

    2017, Cell Chemical Biology
    Citation Excerpt :

    Based on these observations, we used an innovative approach to drug discovery, termed HTS by NMR, that takes advantage of modern fragment-based drug discovery principles, combinatorial chemistry, and NMR-based screening to identify novel initial hit molecules and characterize their binding mode on the surface of the target (Barile and Pellecchia, 2014; Bottini et al., 2015; Wu et al., 2013, 2015a). Here, instead of testing by NMR mixtures of possible fragments and subsequently synthesizing bidentate agents after pairs of ligands have been discovered (Becattini and Pellecchia, 2006; Chen et al., 2007; Petros et al., 2010; Shuker et al., 1996), we combine the fragments directly into a common scaffold and test by NMR the pre-assembled molecules in mixtures gathered in positional scanning fashion (Wu et al., 2013, 2015a). These studies led to the identification of the initial hit molecule compound 22 (Table 1) that was able to bind selectively to the EphA4-LBD in the mid-micromolar range.

  • Fragment-Based Drug Design by NMR

    2017, Encyclopedia of Spectroscopy and Spectrometry
View all citing articles on Scopus
View full text